COVID-19 studies for: C19 studies:  HC QHC Q Vitamin DVitamin D IvermectinIVM LY-CoVLY REGN-COV2REGN RemdesivirRMD ZincZn
HC Q study #61
Source   PDF   Share   Tweet
See all 155 studies
Late treatment study
Sbidian et al., medRxiv, doi:10.1101/2020.06.16.20132597 (Preprint)
Hydroxych loroquine with or without azithromycin and in-hospital mortality or discharge in patients hospitalized for COVID-19 infection: a cohort study of 4,642 in-patients in France
Retrospective of 4,642 hospitalized patients in France showing significantly faster discharge with HC Q and HC Q+AZ. No significant effect is seen on 28-day mortality, however many more control patients are still in hospital at 28 days. Other studies show faster resolution for HC Q, suggesting there will be a significant improvement when extending past 28 days. Hopefully authors will extend the analysis. Note that the median age is higher in the group not treated with HC Q or AZ.
For other issues with the adjustments see [1]. Also see the analysis here [2].
death, ↑5.0%, p=0.74
no hospital discharge, ↓20.0%, p=0.002
Source   PDF   Share   Tweet
See all 155 studies
Please send us corrections, updates, or comments.